Literature DB >> 23955119

Carcinoid valve disease.

J Wells Askew1, Heidi M Connolly.   

Abstract

OPINION STATEMENT: Carcinoid is a rare neuroendocrine tumor that typically originates in the gastrointestinal tract and can result in a constellation of symptoms, mediated by vasoactive substances, referred to as carcinoid syndrome. Carcinoid valve and heart disease is characterized by the plaque-like, endocardial fibrous tissue deposits, primarily affecting the right heart endocardium and valves, which result as a consequence of the disease process. Potential mechanisms for the carcinoid valve disease include the complex role of excess serotonin and its interaction with serotonin receptors and transporters. Carcinoid valve and heart disease is a frequent occurrence in patients with carcinoid syndrome and is accountable for substantial morbidity and mortality. Cardiac surgery remains the most effective treatment option for carcinoid valve disease and a multidisciplinary approach at an experienced center is recommended for patients with metastatic carcinoid and carcinoid heart disease.

Entities:  

Year:  2013        PMID: 23955119     DOI: 10.1007/s11936-013-0265-2

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  56 in total

1.  Quadruple valve replacement in patients with carcinoid heart disease.

Authors:  Arman Arghami; Heidi M Connolly; Martin D Abel; Hartzell V Schaff
Journal:  J Thorac Cardiovasc Surg       Date:  2010-06-26       Impact factor: 5.209

2.  Bioprosthetic tricuspid valve stenosis associated with extensive plaque deposition in carcinoid heart disease.

Authors:  P M Ridker; G M Chertow; E W Karlson; A S Neish; F J Schoen
Journal:  Am Heart J       Date:  1991-06       Impact factor: 4.749

3.  Plasma atrial natriuretic peptide in carcinoid heart disease.

Authors:  L Lundin; K Oberg; J Landelius; H E Hansson; E Wilander; E Theodorsson
Journal:  Am J Cardiol       Date:  1989-04-15       Impact factor: 2.778

4.  Serotonin release into blood after food and pentagastrin. Studies in healthy subjects and in patients with metastatic carcinoid tumors.

Authors:  G Richter; F Stöckmann; J M Conlon; W Creutzfeldt
Journal:  Gastroenterology       Date:  1986-09       Impact factor: 22.682

5.  A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors.

Authors:  S M Ansell; H C Pitot; P A Burch; L K Kvols; M R Mahoney; J Rubin
Journal:  Cancer       Date:  2001-04-15       Impact factor: 6.860

6.  Surgical excision of right ventricular carcinoid tumor in a symptomatic patient without carcinoid valve disease.

Authors:  Basar Sareyyupoglu; Heidi M Connolly; Hartzell V Schaff
Journal:  J Thorac Cardiovasc Surg       Date:  2010-04-02       Impact factor: 5.209

7.  Evaluation of right ventricular dysfunction by myocardial strain echocardiography in patients with intestinal carcinoid disease.

Authors:  Kristina H Haugaa; Deidi S Bergestuen; Laura G Sahakyan; Helge Skulstad; Svend Aakhus; Espen Thiis-Evensen; Thor Edvardsen
Journal:  J Am Soc Echocardiogr       Date:  2011-03-25       Impact factor: 5.251

8.  Prognosis of carcinoid heart disease: analysis of 200 cases over two decades.

Authors:  Jacob E Møller; Patricia A Pellikka; Alain M Bernheim; Hartzell V Schaff; Joseph Rubin; Heidi M Connolly
Journal:  Circulation       Date:  2005-11-14       Impact factor: 29.690

9.  An analysis of 8305 cases of carcinoid tumors.

Authors:  I M Modlin; A Sandor
Journal:  Cancer       Date:  1997-02-15       Impact factor: 6.860

10.  Role of hepatic resection for patients with carcinoid heart disease.

Authors:  Alain M Bernheim; Heidi M Connolly; Joseph Rubin; Jacob E Møller; Christopher G Scott; David M Nagorney; Patricia A Pellikka
Journal:  Mayo Clin Proc       Date:  2008-02       Impact factor: 7.616

View more
  8 in total

1.  Cabergoline for hyperprolactinemia: getting to the heart of it.

Authors:  Lisa B Nachtigall
Journal:  Endocrine       Date:  2017-03-04       Impact factor: 3.633

Review 2.  Ileal neuroendocrine tumors and heart: not only valvular consequences.

Authors:  Jan Calissendorff; Eva Maret; Anders Sundin; Henrik Falhammar
Journal:  Endocrine       Date:  2014-10-16       Impact factor: 3.633

3.  Carcinoid Heart Disease: Starting From Heart Failure.

Authors:  Nicole Bertin; Serena Favretto; Francesco Pelizzo; Lucio Mos; Franco Pertoldi; Olga Vriz
Journal:  J Investig Med High Impact Case Rep       Date:  2017-06-08

4.  Measurement of urinary 5-HIAA: correlation between spot versus 24-h urine collection.

Authors:  Matilde Calanchini; Michael Tadman; Jesper Krogh; Andrea Fabbri; Ashley Grossman; Brian Shine
Journal:  Endocr Connect       Date:  2019-08-01       Impact factor: 3.335

Review 5.  Multimodality imaging in carcinoid heart disease.

Authors:  Ali M Agha; Juan Lopez-Mattei; Teodora Donisan; Dinu Balanescu; Cezar A Iliescu; Jose Banchs; Peter Y Kim; Nicolas L Palaskas; Syed Yusuf; Greg Gladish; Saamir Hassan
Journal:  Open Heart       Date:  2019-06-04

6.  A clinical and echocardiographic case report of carcinoid-related valvular heart disease.

Authors:  Ali J Ebrahimi; Peter Marogil; Gregory Von Mering; Mustafa Ahmed
Journal:  Eur Heart J Case Rep       Date:  2020-11-06

7.  European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease.

Authors:  Simona Grozinsky-Glasberg; Joseph Davar; Johannes Hofland; Rebecca Dobson; Vikas Prasad; Andreas Pascher; Timm Denecke; Margot E T Tesselaar; Francesco Panzuto; Anders Albåge; Heidi M Connolly; Jean-Francois Obadia; Rachel Riechelmann; Christos Toumpanakis
Journal:  J Neuroendocrinol       Date:  2022-05-25       Impact factor: 3.870

Review 8.  Carcinoid Heart Disease: How to Diagnose and Treat in 2020?

Authors:  Barbara Bober; Marek Saracyn; Maciej Kołodziej; Łukasz Kowalski; Elżbieta Deptuła-Krawczyk; Waldemar Kapusta; Grzegorz Kamiński; Olga Mozenska; Jacek Bil
Journal:  Clin Med Insights Cardiol       Date:  2020-10-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.